MabDesign’s market analyses give you a monthly overview of market dynamics and projects in development for a given indication or technology, to help you better understand the constantly evolving market of biologics and biomanufacturing. This month, an overview of the market and projects currently under development for the treatment of multiple sclerosis.
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system, causing progressive deterioration of motor and cognitive functions. It affects women two to three times more often than men, and the average age at diagnosis is young, between 20 and 40 years old. Its annual incidence is estimated at 2.5 to 5 cases per 100,000 population, and its prevalence at 35.9 per 100,000.
Epidemiological data
2,5-5
incidence per 100,000 inhabitants
35,9
prevalence per 100,000 inhabitants
2x to 3x
more women than men affected
Multiple sclerosis market and pipeline
As in the global drug market, the multiple sclerosis treatment market is dominated by small molecules, with only 5.9% of available products being biologics.
By contrast, the boom in biopharmaceuticals and the hope they hold for the treatment of MS is illustrated by the pipeline, which contains 49.8% biopharmaceuticals.
Products on the market
Pipeline
The pipeline is rich, with 506 products currently in development targeting the treatment of different types of multiple sclerosis.
Many different therapeutic strategies are explored in the products under development: vaccines, monoclonal antibodies, gene and cell therapies, etc.
53 products are already in the clinical phase, monoclonal antibodies being the most advanced type of product: 9 mAbs are in phase III and one is currently in pre-registration. The product in pre-registration is ocrelizumab, a new formulation of an anti-CD20 antibody, which enables the product to be administered with two annual 10-minute subcutaneous injections, instead of intravenous infusions, which are more restrictive for patients.
Pipeline par type de biomédicaments et phase de développement
No Data Found
*including recombinant and fusion proteins
Want to find out more?
MabDesign has acquired and cultivates its expertise in all market segments associated with biopharmaceuticals and biomanufacturing. Our team of consultants is at your disposal to support you in all your biotherapy-related projects. Feel free to explore our range of services, including our marketing and strategic analyses, if you’d like to find out more!
Sources: MabDesign & GlobalData
Date – August 2024
